Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.31 |
| ▸ | MEN1 | O00255 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | HTT | P42858 | 1/20 | 0.31 |
| ▸ | HBB | P68871 | 1/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.31 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10185161 | 0.79 | ALDH1A1 (0.32) | ALDH1A1L3MBTL1 | |
| SCHEMBL15173687 | 0.70 | GAA (0.35) | ALDH1A1L3MBTL1MAPTMEN1MAPK1 | |
| SCHEMBL15173686 | 0.70 | GAA (0.35) | ALDH1A1L3MBTL1MAPTMEN1MAPK1 | |
| SCHEMBL15184349 | 0.70 | GAA (0.35) | ALDH1A1L3MBTL1MAPTMEN1MAPK1 | |
| SCHEMBL26860462 | 0.66 | TDP1 (0.31) | — | |
| SCHEMBL15184556 | 0.66 | L3MBTL1 (0.32) | L3MBTL1MAPTMEN1MAPK1HTT | |
| SCHEMBL10185179 | 0.65 | UHRF1 (0.34) | — | |
| SCHEMBL279459 | 0.64 | ALOX15 (0.40) | ALDH1A1L3MBTL1MAPTMEN1MAPK1 | |
| SCHEMBL274106 | 0.64 | ALOX15 (0.40) | ALDH1A1L3MBTL1MAPTMEN1MAPK1 | |
| SCHEMBL31349623 | 0.64 | KMT2A (0.36) | ALDH1A1L3MBTL1MAPTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | SUNESIS PHARMACEUTICALS, INC. | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040951-A1 | HETEROARYL COMPOUNDS USEFUL AS RAF KINASE INHIBITORS | BRAF, RAF1, ARAF | ALDH1A1 1934/4885L3MBTL1 2555/4885MAPT 4105/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.